|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Acambis plc, of Cambridge, UK, began a Phase II trial of its MVA smallpox vaccine, MVA3000. Acambis is co-developing MVA3000 with its process development and manufacturing partner, Baxter Healthcare SA. MVA3000 is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema. The randomized, double-blind, placebo-controlled study will involve 700 healthy adults, half of whom have been previously vaccinated against smallpox.
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., said its board approved a rights agreement under which its stockholders ...